GlycoT Awarded Phase I SBIR Grant

July 27, 2017

GlycoT was awarded a Phase I SBIR grant (1R43GM123823-01A1, $218,846) from the National Institute of General Medical Sciences (NIGMS) to establish a robust and scalable process for production of hypersialylated glycoforms of intravenous immunoglobulin (IVIG) with markedly enhanced anti-inflammatory activity.

Research and Development Collaborations
To request a quote for our products, customized service, investment opportunities, or if you have any general inquiry for our company click the start now button.
Learn More